Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice

Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice

Background and ObjectivesMyasthenia gravis (MG) is a T cell-dependent, B cell-mediated autoimmune disease targeting the acetylcholine receptor (AChR) and other proteins of the neuromuscular junction postsynaptic membrane. Production of pathogenic autoantibodies results from B cell activation and exp...

Full description

Saved in:
Bibliographic Details
Main Authors: Elena Rinaldi, Elisa Puleo, Alessandra Consonni, Martina Miglietti, Renato Mantegazza, NingXin Wang, Stanford L. Peng, Katherine E. Lewis, Stacey R. Dillon, Fulvio Baggi
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
BAFF - B-cell activating factor
APRIL (TNFSF13)
myasthenia gravis
experimental autoimmune myasthenia gravis
animal model
TACI (TNFRSF13B)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1533093/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1533093/full

Similar Items